Prakiraan wutah bathi resik saben saham kanggo taun ngarep Collegium Pharmaceutical Inc (COLL)
The forward earnings per share growth forecast demonstrates Collegium Pharmaceutical (COLL) battling regulators and generics through unique defensive technologies. Agile management is successfully diversifying the portfolio by integrating new assets. Stable income is secured by patents for chronic pain medications, and -5.30 serves as the final mark for this metric.
Rincian metrik lan analitis perusahaan collegiumpharma.com (COLL)
- rega saham lan konsensus proyeksi valuasi:
- rincian kapitalisasi pasar:
- rincian nilai buku perusahaan:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Collegium Pharmaceutical|COLL - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Collegium Pharmaceutical, Inc.|COLL - Tanggungan utang total perusahaan|Utang-utang marang kapitalisasi buku Collegium Pharmaceutical|COLL - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan Collegium Pharmaceutical|Likuiditas cepet collegiumpharma.com
- data bathi resik lan rasio valuasi:
COLL - Penghasilan resik|Bathi mangsa ngarep Collegium Pharmaceutical|COLL - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Collegium Pharmaceutical|COLL - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA Collegium Pharmaceutical|COLL - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Collegium Pharmaceutical|COLL - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan collegiumpharma.com|COLL - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Collegium Pharmaceutical
- statistik dodolan lan pendapatan perusahaan:
Analisis kabeh metrik perusahaan:Collegium Pharmaceutical Inc, COLL
This metric measures the expected increase in earnings per share, reflecting the analysts' consensus forecast for the business's operational efficiency. The current value of -5.30 is based on the potential for implementing proprietary drug delivery technologies in the US, allowing investors to assess the risk of overpayment by analyzing the projected annual EPS dynamics of Collegium Pharmaceutical (COLL) on this chart.
Analisis pesaing
INDV (Indivior Group) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi saben saham kanggo taun ngarep Cronos Corp (CRON)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Canopy Growth (CGC)|HITI - Prakiraan wutah bathi resik saben saham ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Aurora Cannabis Inc. ACB|Achieve Life Sciences Inc. - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|SKYE - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|ANEB: Prakiraan wutah bathi resik saben saham kanggo taun ngarep|INCR: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Nutriband (NTRB)|NSRX (Nasus Pharma Ltd.) - Prakiraan wutah bathi kanggo taun ngarep|IGC - Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep MIRA|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Flora Growth Inc|IM Cannabis - Prakiraan wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep Adial Pharmaceuticals Inc. ADIL|ARTL - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Ensysce Biosciences (ENSC) - Prakiraan wutah bathi saben saham kanggo taun ngarep|TTNP (titanpharm.com) - Prakiraan wutah bathi saben saham kanggo taun ngarep|Greenlane Corp - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep InMed Pharmaceuticals|akandacorp.com - Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep ENVB|BGXX (brightgreen.us) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep HPCO (Hempacco Co., Inc.)
